NASDAQ:KZIA Kazia Therapeutics - KZIA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. $1.00 -0.01 (-0.99%) (As of 01/27/2023 08:55 PM ET) Add Compare Share Share Today's Range$0.97▼$1.0450-Day Range$0.50▼$1.0552-Week Range$0.50▼$8.61Volume32,100 shsAverage Volume104,019 shsMarket Capitalization$13.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Kazia Therapeutics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.78% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.25Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.05) to ($1.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.87 out of 5 starsMedical Sector1045th out of 1,049 stocksPharmaceutical Preparations Industry510th out of 514 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Kazia Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.78% of the outstanding shares of Kazia Therapeutics have been sold short.Short Interest Ratio / Days to CoverKazia Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kazia Therapeutics has recently increased by 64.19%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKazia Therapeutics does not currently pay a dividend.Dividend GrowthKazia Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KZIA. Previous Next 1.0 News and Social Media Coverage News SentimentKazia Therapeutics has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kazia Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Kazia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kazia Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Kazia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.47% of the stock of Kazia Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kazia Therapeutics are expected to grow in the coming year, from ($1.05) to ($1.01) per share.Price to Book Value per Share RatioKazia Therapeutics has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kazia Therapeutics (NASDAQ:KZIA) StockKazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.Read More Receive KZIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KZIA Stock News HeadlinesJanuary 25, 2023 | finance.yahoo.comTrade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More SharesJanuary 24, 2023 | americanbankingnews.comKazia Therapeutics Limited (NASDAQ:KZIA) Sees Large Decline in Short InterestJanuary 30, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 18, 2023 | finance.yahoo.comKazia Therapeutics CEO talks $4.5 million capital raiseJanuary 16, 2023 | msn.comKazia raises A$4.5M to progress R&D programsJanuary 16, 2023 | finance.yahoo.comKAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMSDecember 20, 2022 | proactiveinvestors.com.auKazia Therapeutics exploring use of lead asset in other cancers: Edison Investment ResearchDecember 19, 2022 | finance.yahoo.comKazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo TherapiesJanuary 30, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 15, 2022 | finance.yahoo.comKAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILINGDecember 12, 2022 | finance.yahoo.comKAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATIONDecember 7, 2022 | proactiveinvestors.comKazia Therapeutics’ upcoming top-line data for EVT801 expected to be a share price catalyst: Edison Investment ResearchDecember 5, 2022 | proactiveinvestors.com.auKazia Therapeutics talks positive pre-clinical data for EVT801November 9, 2022 | finance.yahoo.comKAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETINGNovember 2, 2022 | seekingalpha.comKazia Therapeutics provides cash outlookNovember 2, 2022 | finance.yahoo.comKazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our EstimatesOctober 27, 2022 | benzinga.comThinking about buying stock in UserTesting, Kazia Therapeutics, Shopify, Ford Motor, or View?October 27, 2022 | seekingalpha.comKazia jumps 31% on pre-clinical data for skin cancer therapyOctober 27, 2022 | finance.yahoo.comKAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMAOctober 27, 2022 | finance.yahoo.comKazia Therapeutics Reveals Paxalisib Preclinical Data In Melanoma Animal ModelsOctober 20, 2022 | uk.investing.comKazia Therapeutics Ltd (KZA)October 6, 2022 | finance.yahoo.comPNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLYOctober 5, 2022 | proactiveinvestors.com.auKazia Therapeutics takes Phase 2 study of paxalisib international; opens two sites in AustraliaSeptember 27, 2022 | reuters.comKazia Therapeutics LtdSeptember 26, 2022 | finance.yahoo.comNovogen Limited (KZIA) Could Find Support Soon, Here's Why You Should Buy the Stock NowSeptember 9, 2022 | finance.yahoo.comKAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCESeptember 8, 2022 | finance.yahoo.comKAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMOSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KZIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KZIA Company Calendar Today1/30/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KZIA CUSIPN/A CIK1075880 Webwww.kaziatherapeutics.com Phone(129) 472-4101Fax61-2-9476-0388Employees2,021Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.62 Quick Ratio1.62 Sales & Book Value Annual Sales$11.35 million Price / Sales1.22 Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book1.03Miscellaneous Outstanding Shares13,880,000Free Float13,737,000Market Cap$13.88 million OptionableNot Optionable Beta2.11 Key ExecutivesJames Stuart GarnerChief Executive Officer, MD & Executive DirectorKaren R. KrumeichChief Financial OfficerJohn E. FriendChief Medical OfficerCatherine HillSecretaryKey CompetitorsVYNE TherapeuticsNASDAQ:VYNEAileron TherapeuticsNASDAQ:ALRNAddex TherapeuticsNASDAQ:ADXNOragenicsNYSE:OGENEvoke PharmaNASDAQ:EVOKView All CompetitorsInsiders & InstitutionsOLD Mission Capital LLCBought 80,923 shares on 11/14/2022Ownership: 0.583%View All Institutional Transactions KZIA Stock - Frequently Asked Questions Should I buy or sell Kazia Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kazia Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" KZIA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZIA, but not buy additional shares or sell existing shares. View KZIA analyst ratings or view top-rated stocks. How have KZIA shares performed in 2023? Kazia Therapeutics' stock was trading at $0.6149 at the beginning of the year. Since then, KZIA stock has increased by 62.6% and is now trading at $1.00. View the best growth stocks for 2023 here. Are investors shorting Kazia Therapeutics? Kazia Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 247,100 shares, an increase of 64.2% from the December 31st total of 150,500 shares. Based on an average daily volume of 350,200 shares, the days-to-cover ratio is currently 0.7 days. View Kazia Therapeutics' Short Interest. What other stocks do shareholders of Kazia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kazia Therapeutics investors own include Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Pfizer (PFE), Translate Bio (TBIO), VYNE Therapeutics (VYNE) and Allena Pharmaceuticals (ALNA). What is Kazia Therapeutics' stock symbol? Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA." How do I buy shares of Kazia Therapeutics? Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kazia Therapeutics' stock price today? One share of KZIA stock can currently be purchased for approximately $1.00. How much money does Kazia Therapeutics make? Kazia Therapeutics (NASDAQ:KZIA) has a market capitalization of $13.88 million and generates $11.35 million in revenue each year. How many employees does Kazia Therapeutics have? The company employs 2,021 workers across the globe. How can I contact Kazia Therapeutics? Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The official website for the company is www.kaziatherapeutics.com. The company can be reached via phone at (129) 472-4101, via email at investment.consultant@novogen.com, or via fax at 61-2-9476-0388. This page (NASDAQ:KZIA) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.